Taisho Pharmaceutical Co., Ltd.

Daisuke Wakasugi

Takeshi Kuwada

Naoki Miyakoshi

Nobutaka Hattori

Youichi Shimazaki

Tomoko Ishizaka

Shin-ichi Shirokawa

Mitsukane Yoshinaga

Hiroshi Ohta

Shuji Yamamoto

Naoya Ono

Yoshinori Sekiguchi

Hajime Asanuma

Takahiro Oi

Tetsuya Yabuuchi

Tetsuo Takayama

Yusuke Oka

Shoichi Kuroda

Madoka Kawamura

Fumito Uneuchi

Xiang-Min Sun

Yuko Araki

Takeshi Koami

Kumi Abe

Minoru Moriya

Rie Nishikawa

Shin-Ichi Shirokawa

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor: 

Azole derivative

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia. 

1, 2, 4-triazolone derivative and use thereof as an antagonist on the arginine-vasopressin 1B receptor

The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Glycine transporter-inhibiting substances

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

Growing community of inventors

Tokyo, Japan

Daisuke Wakasugi